Skip to main content

LANDING PAD THP1 MONOCYTES ANNUAL LICENSE

Catalog No.
C005B-247931
Manufacturer No.
CLL1223A-1VL
Manufacturer Name
Sigma-Aldrich
Quantity
1
Unit of Measure
VL

General description The STR profile of this cell line matches that of its parental cell line ATCC ®: Catalog No. TIB-202.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

General description

The STR profile of this cell line matches that of its parental cell line ATCC®Catalog No. TIB-202. THP-1 are a human monocyte cell line isolated from the peripheral blood of a male infant with acute monocytic leukemia. The cells are phagocytic and lack surface and cytoplasmic immunoglobulins. Differentiation can be induced with TPA.

Cell Line Description

These cells were derived from the peripheral blood of a 1-year old male with acute monocytic leukemia. These cells have Fc and C3b receptors and lack surface and cytoplasmic immunoglobulins. They stain positive for α-napthhyl butyrate esterase, produce lysozymes, and are phagocytic (both latex beads and sensitized erythrocytes). They can restore the response of purified T lymphocytes to Concanavalin A, show increased CO2 production on phagocytosis, and can be differentiated into macrophage-like cells using, for example, DMSO.

Application

This product is a human THP-1 monocyte cell line in which a landing pad cassette has been integrated into the AAVS1 safe harbor locus using CompoZr® Zinc Finger Nuclease technology. The mKATE2 fluorescence gene was integrated following the EF1a promoter and flanked by unique Cre-lox sites. The design of this landing pad cassette allows for easy, fast, and affordable genetic modification using Cre recombinase. mKATE2 can easily be exchanged for a payload of the user′s choice using Cre recombinase and a targeting vector with appropriate lox sites. Cells can then be sorted via fluorescence-activated cell sorting (FACS) for loss of mKATE2 expression as a surrogate for successful integration of the targeting vector. Approximately 7-10 days are required for loss of the mKATE2 signal in successfully targeted cells. See technical bulletin for detailed protocols.

Features and Benefits

These cells contain the mKATE2 fluorescence gene flanked by unique Cre-lox sites inserted in the AAVS1 safe harbor gene. These THP-1 cells are grown in suspension with a doubling time of approximately 24 hours.

Quality

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, short terminal repeat (STR) analysis for cell line identification.

Legal Information

ATCC is a registered trademark of American Type Culture Collection

CompoZr is a registered trademark of Sigma-Aldrich Co. LLC

UPC:
51131809
Condition:
New
HazmatClass:
Yes
MPN:
CLL1223A-1VL

Cenmed Satisfaction Guarantee
Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

Testimonial
"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."

LAB DIRECTOR

Testimonial
"We utilized Cenmed's capabilities for a variety of projects around the world. They are a valued partner and supplier."

PHARMACEUTICAL SUPPLY CHAIN LEADER

Testimonial
"The reps are very good at finding products for customers in this period of supply chain issues."

SCOTT BEHMAN

Testimonial
"Your customer service has been excellent and makes me excited about purchasing with Cenmed in the future!!"

PROCUREMENT + BILLING COORDINATOR AT PHARMA.